262 related articles for article (PubMed ID: 27016308)
1. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
2. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
3. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
4. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
5. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
6. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
7. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
Callahan MJ; Nagymanyoki Z; Bonome T; Johnson ME; Litkouhi B; Sullivan EH; Hirsch MS; Matulonis UA; Liu J; Birrer MJ; Berkowitz RS; Mok SC
Clin Cancer Res; 2008 Dec; 14(23):7667-73. PubMed ID: 19047092
[TBL] [Abstract][Full Text] [Related]
8. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
[TBL] [Abstract][Full Text] [Related]
9. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.
Montfort A; Pearce O; Maniati E; Vincent BG; Bixby L; Böhm S; Dowe T; Wilkes EH; Chakravarty P; Thompson R; Topping J; Cutillas PR; Lockley M; Serody JS; Capasso M; Balkwill FR
Clin Cancer Res; 2017 Jan; 23(1):250-262. PubMed ID: 27354470
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
Liao C; Wang A; Ma Y; Liu H
Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
[TBL] [Abstract][Full Text] [Related]
12. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
14. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
Rüder U; Denkert C; Kunze CA; Jank P; Lindner J; Jöhrens K; Kulbe H; Sehouli J; Dietel M; Braicu E; Darb-Esfahani S
Histol Histopathol; 2019 Apr; 34(4):405-417. PubMed ID: 30289149
[TBL] [Abstract][Full Text] [Related]
16. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
18. High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.
Droeser RA; Güth U; Eppenberger-Castori S; Stadlmann S; Hirt C; Terracciano L; Singer G
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1295-302. PubMed ID: 23624523
[TBL] [Abstract][Full Text] [Related]
19. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
20. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
